Disease Focus
Our development programs are designed to address the critical challenge of cancer mutations that become resistant to treatment.
Theseus is developing pan-variant tyrosine kinase inhibitors (TKIs) for clinically validated cancer targets with clear unmet medical need. Existing TKIs are limited by constantly mutating cancers, and data demonstrate that these TKIs are unable to overcome a broad array of resistance mutations to inhibit their targets successfully.
We are developing pan-variant tyrosine kinase inhibitors for clinically validated targets in cancers with clear unmet medical need.
Our lead candidate, THE-630, is a single molecule pan-variant inhibitor of the tyrosine kinase KIT in development for gastrointestinal stromal tumors (GIST), the most common sarcoma of the gastrointestinal tract with 4,000-6,000 new cases diagnosed in the U.S. each year.
Our second candidate is a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor in development for non-small cell lung cancer (NSCLC) that has become resistant to previous lines of targeted treatment.
We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in tyrosine kinase targets.
VIEW OUR PIPELINE